Case. A 34-year-old African-American female with a history of adult-onset Still’s disease presented to an outside hospital with oligoarthritis. She experienced a generalized tonic-clonic seizure en route via ambulance, was intubated upon arrival, and transferred to the intensive care unit for treatment of suspected pneumonia and sepsis. She subsequently developed generalized cutaneous desquamation that progressed despite the cessation of antibiotics and other potential offending drugs which required transfer to our hospital’s burn unit. She was suspected to have reactive hemophagocytic syndrome based on her clinical presentation of fever, rash, polyarthritis, elevated liver enzymes, coagulopathy, splenomegaly, normocytic anemia, thrombocytopenia, hypertriglyceridemia, hyperferritinemia, and hemophagocytosis visualized in bone marrow biopsy specimen. Magnetic resonance imaging demonstrated necrotic demyelination of the deep white matter and corona radiata. The patient developed multiorgan dysfunction and DIC without any other attributable etiology. Despite aggressive broad spectrum therapy and high dose of steroids she progressively deteriorated and eventually expired. Conclusion. Previous publications have highlighted the prevalence of necrotic leukoencephalopathy in children with familial hemophagocytic syndrome. Our patient demonstrated some uncommon features complicating her HLH including DIC and necrotic leukoencephalopathy, which are very rare entities in AOSD. 1. Introduction Still’s disease was first described by George Still in 1896. Adult-onset Still’s disease (AOSD) describes a similar condition which affects adults and is generally constituted by recurrent high grade fever with concomitant salmon-colored rash of the trunk and extremities, oligo- and later polyarthritis, pharyngitis, splenomegaly, lymphadenopathy, and less commonly pericarditis or pleural effusions [1]. Laboratory evaluation typically demonstrates elevated erythrocyte sedimentation rate, leukocytosis, and elevated liver enzymes [2]. Hemophagocytic syndrome (HS), also termed hemophagocytic lymphohistiocytosis (HLH), is a syndrome of immune activation manifested by signs and symptoms of inflammation [3]. HS is diagnosed based on the fulfillment of 5/8 criteria as in Table 1 [4]. Histopathological evaluation demonstrates lymphocytes, macrophages and hemophagocytosis in bone marrow, spleen, cerebral spinal fluid, and liver [4]. Other common clinical manifestations include central nervous system involvement, coagulopathy, liver dysfunction, jaundice, edema, and skin rashes [4]. A
References
[1]
P. Efthimiou and S. Georgy, “Pathogenesis and management of adult-onset Still's disease,” Seminars in Arthritis and Rheumatism, vol. 36, no. 3, pp. 144–152, 2006.
[2]
J. Pouchot, J. S. Sampalis, F. Beaudet et al., “Adult Still's disease: manifestations, disease course, and outcome in 62 patients,” Medicine, vol. 70, no. 2, pp. 118–136, 1991.
[3]
M. B. Jordan, C. E. Allen, S. Weitzman, A. H. Filipovich, and K. L. McClain, “How I treat hemophagocytic lymphohistiocytosis,” Blood, vol. 118, no. 15, pp. 4041–4052, 2011.
[4]
J.-I. Henter, A. Horne, M. Aricó et al., “HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis,” Pediatric Blood and Cancer, vol. 48, no. 2, pp. 124–131, 2007.
[5]
E. Haddad, M.-L. Sulis, N. Jabado, S. Blanche, A. Fischer, and M. Tardieu, “Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis,” Blood, vol. 89, no. 3, pp. 794–800, 1997.
[6]
S. S. Kollias, W. S. Ball Jr., A. A. Tzika, and R. E. Harris, “Familial erythrophagocytic lymphohistiocytosis: neuroradiologic evaluation with pathologic correlation,” Radiology, vol. 192, no. 3, pp. 743–754, 1994.
[7]
A. Hot, M.-L. Toh, B. Coppéré et al., “Reactive hemophagocytic syndrome in adult-onset still disease: clinical features and long-term outcome: a case-control study of 8 patients,” Medicine, vol. 89, no. 1, pp. 37–46, 2010.
[8]
R. Dhote, J. Simon, T. Papo et al., “Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review,” Arthritis Care and Research, vol. 49, no. 5, pp. 633–639, 2003.
[9]
J. A. Morris, A. R. Adamson, P. J. L. Holt, and J. Davson, “Still's disease and the virus-associated haemophagocytic syndrome,” Annals of the Rheumatic Diseases, vol. 44, no. 5, pp. 349–353, 1985.
[10]
A. H. Filipovich, “Hemophagocytic lymphohistiocytosis and related disorders,” Current Opinion in Allergy and Clinical Immunology, vol. 6, no. 6, pp. 410–415, 2006.
[11]
G. E. Janka, “Hemophagocytic syndromes,” Blood Reviews, vol. 21, no. 5, pp. 245–253, 2007.
[12]
B. Fautrel, G. le Mo?l, B. Saint-Marcoux et al., “Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease,” Journal of Rheumatology, vol. 28, no. 2, pp. 322–329, 2001.
[13]
A. Karras and O. Hermine, “Macrophage activation syndrome,” La Revue de Médecine Interne, vol. 23, pp. 768–778, 2002.
[14]
A. V. Ramanan and R. Schneider, “Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis,” Journal of Rheumatology, vol. 30, no. 2, pp. 401–403, 2003.
[15]
B. Fautrel, E. Zing, J.-L. Golmard et al., “Proposal for a new set of classification criteria for adult-onset still disease,” Medicine, vol. 81, no. 3, pp. 194–200, 2002.
[16]
O. Lambotte, P. Cacoub, N. Costedoat-Chalumeau, G. le Moel, Z. Amoura, and J.-C. Piette, “High ferritin and low glycosylated ferritin may also be a marker of excessive macrophage activation,” Journal of Rheumatology, vol. 30, no. 5, pp. 1027–1028, 2003.
[17]
U. Emmenegger, U. Frey, A. Reimers et al., “Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes,” The American Journal of Hematology, vol. 68, no. 1, pp. 4–10, 2001.
[18]
D.-B. Zhao, S.-M. Dai, X.-P. Liu, and H. Xu, “Interstitial inflammation in visceral organs is a pathologic feature of adult-onset Still's disease,” Rheumatology International, vol. 31, no. 7, pp. 923–927, 2011.
[19]
M. Meeths, M. Entesarian, W. Al-Herz et al., “Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2,” Blood, vol. 116, no. 15, pp. 2635–2643, 2010.
[20]
M. A. Hamidou, M. Denis, S. Barbarot, D. Boutoille, C. Belizna, and G. le Mo?l, “Usefulness of glycosylated ferritin in atypical presentations of adult onset Still's disease,” Annals of the Rheumatic Diseases, vol. 63, no. 5, p. 605, 2004.